Oramed Pharmaceuticals completes Phase 2b study of ORMD-0801 oral insulin capsule

Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) announced today the completion of its' pivotal Phase 2b clinical study of its oral insulin capsule, ORMD-0801. The Company expects to report results from this study within the coming weeks.

The Phase 2b trial is a randomized, double-blind, placebo-controlled, multi-centered study, that primary evaluated the safety, and tolerability of Oramed's oral insulin delivery technology. The study took place in five locations throughout South Africa and was monitored by OnQ Consulting, a clinical research organization (CRO) based in Johannesburg, South Africa.

"The completion of the Phase 2b clinical trial for ORMD-0801 is a significant milestone for Oramed," said Nadav Kidron, Chief Executive Officer of the Company, who continued, "We are especially thankful for the dedication of all the investigators who participated in the study."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Flight altitude changes may affect blood glucose levels of type 1 diabetes patients using insulin pumps